test

Developmental Therapeutics

John D Roberts MD

Professor of Medicine (Medical Oncology); Medical Director, Adult Sickle Cell Program at Yale-New Haven Hospital

Clinical Interests

sickle cell disease; medical oncology phase I trials; urological cancers (prostate, bladder, testicle)


Board Certifications

2012
Hospice & Palliative Medicine, Board Certified
1985
Medical Oncology, Board Certified
1980
Internal Medicine, Board Certified

Patient Care Locations

john_d_robertsfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
ProstateSWOG S1216: A PHASE III RANDOMIZED TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY + TAK-700 WITH ANDROGEN DEPRIVATION THERAPY + BICALUTAMIDE IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, and ThyroidA Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
ProstatePhase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer maintained on androgen deprivation therapy
Bladder, Breast - Female, Breast - Male, Colon, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Skin, Other Urinary, Pancreas, Prostate, Small Intestine, Soft Tissue, and StomachA Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects with Advanced Tumors
Other Digestive Organ and Unknown SitesModular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors

More Clinical Trials...

Edit Profile